Resection of retroperitoneal residual tumor after chemotherapy for testicular cancer indication and surgical techniques

Critical Reviews in Oncology/Hematology

Volumn 50, Issue 1, 2004, Pages 79-85

  Albers, Peter ^a,b  

^a UNIVERSITY OF BONN   (Germany)

^b KLINIKUM KASSEL   (Germany)

Author keywords

Chemotherapy; Residual tumor resection; Testis cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; IFOSFAMIDE; PACLITAXEL; VINBLASTINE;

CANCER CHEMOTHERAPY; CANCER SURGERY; CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; DEBRIDEMENT; EJACULATION; FROZEN SECTION; HISTOLOGY; HUMAN; LAPAROSCOPY; METASTASIS; MINIMAL RESIDUAL DISEASE; MORBIDITY; NECROSIS; NEPHRECTOMY; NON SEMINOMATOUS GERMINOMA; RETROPERITONEAL TUMOR; REVIEW; SALVAGE THERAPY; SEMINOMA; SURGICAL TECHNIQUE; TECHNIQUE; TERATOMA; TESTIS CANCER; YOLK SAC;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; HUMANS; MALE; RETROPERITONEAL NEOPLASMS; SURGICAL PROCEDURES, OPERATIVE; TESTICULAR NEOPLASMS;

EID: 16544383120     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(03)00121-5     Document Type: Review

References (50)

1. Vuky J., Tickoo S.K., Sheinfeld J., et al. Salvage chemotherapy for patients with advanced pure seminoma. J. Clin. Oncol. 20:2002;297-301.
2. Miller K.D., Loehrer P.J., Gonin R., et al. Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin in recurrent seminoma. J. Clin. Oncol. 15:1997;1427-1431.
3. Herr H.W., Sheinfeld J., Puc H.S., et al. Surgery for a post-chemotherapy residual mass in seminoma. J. Urol. 157:1997;860-862.
4. von der Maase H., Specht L., Jacobsen G.K., et al. Surveillance following orchidectomy for stage I seminoma of the testis. Eur. J. Cancer. 29A:1993;1931-1934.
5. Albers P., Weinknecht S., Krege S., et al. Prediction of necrosis after chemotherapy of advanced germ cell tumors - results of a prospective multicenter trial of the GTCSG. J. Urol. 167:2002;172. (abstract).
6. De Santis M., Bokemeyer C., Becherer A., et al. Predictive impact of 2-18fluoro-2deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma. J. Clin. Onco. 19:2001;3740-3744.
7. Mosharafa A.A., Foster R.S., Leibovich B.C., et al. Is the postchemotherapy resection of seminomatous elements associated with higher acute morbidity. J. Urol. 167:2002;172. (abstract).
8. Steyerberg E.W., Keizer H.J., Fossa S.D., et al. Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups. J. Clin. Oncol. 13:1995;1177-1187.
9. Steyerberg E.W., Keizer H.J., Habbema J.D. Prediction models for the histology of residual masses after chemotherapy for metastatic testicular cancer. ReHiT Study Group. Int. J. Cancer. 83:1999;856-859.
10. Debono D.J., Heilman D.K., Einhom L.H., et al. Decision analysis for avoiding postchemotherapy surgery in patients with disseminated nonseminomatous germ cell tumors. J. Clin. Oncol. 15:1997;1455-1464.
11. Logothetis C.J., Samuels M.L., Trinadade A., et al. The growing teratoma syndrome. Cancer. 50:1982;1629-1635.
12. Ganjoo K.N., Foster R.S., Michael H., et al. Germ cell tumor associated primitive neuroectodermal tumors. J. Urol. 165:2001;1514-1516.
13. Albers P., Ganz A., Hannig E., et al. Salvage surgery of chemorefractory germ cell tumors with elevated tumor markers. J. Urol. 164:2000;381-384.
14. Eastham J.A., Wilson T.G., Russell C., et al. Surgical resection in patients with nonseminomatous germ cell tumor who fail to normalize serum tumor markers after chemotherapy. Urology. 43:1994;74-80.
15. Murphy B.R., Breeden E.S., Donohue J.P. Surgical salvage of chemorefractory germ cell tumors. J. Clin. Oncol. 11:1993;324-329.
16. Weinknecht S., Bussar-Maatz R., Albers P., et al. Is the resection of residual tumors in patients with germ cell tumors and positive markers justified. Urologe A. 37:1997;68. (abstract).
17. Wood D.P., Herr H.W., Motzer R.J., et al. Surgical resection of solitary metastases after chemotherapy in patients with nonseminomatous germ cell tumors and elevated serum tumor markers. Cancer. 70:1992;2354-2357.
18. Fossa S.D., Qvist H., Stenwig A.E., et al. Is postchemotherapy retroperitoneal surgery necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses. J. Clin. Oncol. 10:1992;569-573.
19. Foster R.S., Donohue J.P. Can retroperitoneal lymphadenectomy be omitted in some patients after chemotherapy. Urol. Clin. N. Am. 25:1998;479-484.
20. Stenning S.P., Parkinson M.C., Fisher C., et al. Postchemotherapy residual masses in germ cell tumor patients: content, clinical features, and prognosis. Medical Research Council Testicular Tumor Working Party. Cancer. 83:1998;1409-1419.
21. Hendry W.F., Norman A.R., Dearnaley D.P., et al. Metastatic nonseminomatous germ cell tumors of the testis: results of elective and salvage surgery for patients with residual retroperitoneal masses. Cancer. 94:2002;1668-1676.
22. Sheinfeld J., Herr H.W. Role of surgery in management of germ cell tumor. Semin. Oncol. 25:1998;203-209.
23. Steyerberg E.W., Gerl A., Fossa S.D., et al. Validity of predictions of residual retroperitoneal mass histology in nonseminomatous testicular cancer. J. Clin. Oncol. 16:1998;269-274.
24. Vergouwe Y., Steyerberg E.W., Foster R.S., et al. Validation of a prediction model and its predictors for the histology of residual masses in nonseminomatous testicular cancer. J. Urol. 165:2001;84-88.
25. Herr H.W. Does necrosis on frozen-section analysis of a mass after chemotherapy justify a limited retroperitoneal resection in patients with advanced testis cancer. Br. J. Urol. 80:1997;653-657.
26. Baniel J., Foster R.S., Einhom L.H., et al. Late relapse of clinical stage I testicular cancer. J. Urol. 154:1995;1370-1372.
27. Gerl A., Clemm C., Schmeller N., et al. Late relapse of germ cell tumors after cisplatinbased chemotherapy. Ann. Oncol. 8:1997;41-47.
28. Arai Y., Ishitoya S., Okubo K., et al. Nerve-sparing retroperitoneal lymph node dissection for metastatic testicular cancer. Int. J. Urol. 4:1997;487-492.
29. Jewett M.A., Kong Y.S., Goldberg S.D., et al. Retroperitoneal lymphadenectomy for testis tumor with nerve sparing for ejaculation. J. Urol. 139:1988;1220-1224.
30. Qvist H., Fossa S.D., Ous S., et al. Retroperitoneal surgery in patients with nonseminomatous testicular cancer and minimal residual tumor. J. Surg. Oncol. 50:1992;220-223.
31. Recker F., Goepel M., Otto T., et al. An intra-operative seminal and prostate emission test as a control for nerve-sparing procedures in primary and secondary retroperitoneal lymphadenectomy. Br. J. Urol. 77:1996;133-137.
32. Wahle G.R., Foster R.S., Bihrle R., et al. Nerve sparing retroperitoneal lymphadenectomy after primary chemotherapy for metastatic testicular carcinoma. J. Urol. 152:1994;428-430.
33. Baniel J., Foster R.S., Rowland R.G., et al. Complications of primary retroperitoneal lymph node dissection. J. Urol. 152:1994;424-427.
34. Baniel J., Foster R.S., Rowland R.G., et al. Complications of post-chemotherapy retroperitoneal lymph node dissection. J. Urol. 153:1995;976-980.
35. Gels M.E., Nijbocr A.P., Hoekstra H.J., et al. Complications of the post-chemotherapy resection of retroperitoneal residual tumor mass in patients with non-seminomatous testicular germ cell tumors. Br. J. Urol. 79:1997;263-268.
36. Jewett M.A., Wesley-James T. Early and late complications of retroperitoneal lymphadenectomy in testis cancer. Can. J. Surg. 34:1991;368-373.
37. Skinner D.O., Melamud A., Lieskovsky G. Complications of thoracoabdominal retroperitoneal lymph node dissection. J. Urol. 127:1982;1107-1110.
38. Heidenreich A., Albers P., Hartmann M., et al. Complications of primary nerve-sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group. J. Urol. 169:2003;1710-1714.
39. Steyerberg E.W., Donohue J.P., Gerl A., et al. Residual masses after chemotherapy for metastatic testicular cancer: the clinical implications of the association between retroperitoneal and pulmonary histology Re-analysis of Histology in Testicular Cancer (ReHiT) Study Group. J. Urol. 158:1997;474-478.
40. Fizazi K., Tjulandin S., Salvioni R., et al. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy - results from an international study group. J. Clin. Oncol. 19:2001;2647-2657.
41. George D.W., Foster R.S., Hromas K.A., et al. Update on late relapse of germ cell tumor: a clinical and molecular analysis. J. Clin. Oncol. 21:2003;113-122.
42. Nelson J.B., Chen R.N., Bishoff J.T., et al. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular tumors. Urology. 54:1999;1064-1067.
43. Rassweiler J.J., Frede T., Lenz E., et al. Long-term experience with laparoscopic retroperitoneal lymph node dissection in the management of low-stage testis cancer. Eur. Urol. 37:2000;251-260.
44. Hobisch A., Peschel R., Höltl L., et al. Experience of more than 150 laparoscopic retroperitoneal lymph node dissections of testicular tumors - technique and results. Eur. Urol. 1:2002;94. (abstract).
45. Janetschek G., Hobisch A., Peschel R., et al. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous testicular carcinoma: long-term outcome. J. Urol. 163:2000;1793-1796.
46. Janetschek G., Peschel R., Hobisch A., et al. Laparoscopic retroperitoneal lymph node dissection. J. Endourol. 15:2001;449-453.
47. LeBlanc E., Caty A., Dargent D., et al. Extraperitoneal laparoscopic para-aortic lymph node dissection for early stage nonseminomatous germ cell tumors of the testis with introduction of a nerve sparing technique: description and results. J. Uro1. 165:2001;89-92.
48. Janetschek G. Laparoscopic retroperitoneal lymph node dissection. Urol. Clin. N. Am. 28:2001;107-114.
49. Höltl L., Peschel R., Knapp R., et al. Primary lymphatic metastatic spread in testicular cancer occurs ventral to the lumbar vessels. Urology. 59:2002;114-118.
50. Steiner H., Peschel R., Höltl L., et al. Laparoscopic retroperitoneal lymph node dissection is feasible after chemotherapy for retroperitoneal stage II nonseminomatous germ cell tumors. J. Urol. 167:2002;170. (abstract).